caa a22 4500 605543089 CHVBK 20210128100924.0 cr unu---uuuuu 210128e20150901xx s 000 0 eng 10.1007/s00109-015-1317-8 doi (NATIONALLICENCE)springer-10.1007/s00109-015-1317-8 Chemokines and their receptors in Atherosclerosis [Elektronische Daten] [Emiel van der Vorst, Yvonne Döring, Christian Weber] Atherosclerosis, a chronic inflammatory disease of the medium- and large-sized arteries, is the main underlying cause of cardiovascular diseases (CVDs) most often leading to a myocardial infarction or stroke. However, atherosclerosis can also develop without this clinical manifestation. The pathophysiology of atherosclerosis is very complex and consists of many cells and molecules interacting with each other. Over the last years, chemokines (small 8-12kDa cytokines with chemotactic properties) have been identified as key players in atherogenesis. However, this remains a very active and dynamic field of research. Here, we will give an overview of the current knowledge about the involvement of chemokines in all phases of atherosclerotic lesion development. Furthermore, we will focus on two chemokines that recently have been associated with atherogenesis, CXCL12, and macrophage migration inhibitory factor (MIF). Both chemokines play a crucial role in leukocyte recruitment and arrest, a critical step in atherosclerosis development. MIF has shown to be a more pro-inflammatory and thus pro-atherogenic chemokine, instead CXCL12 seems to have a more protective function. However, results about this protective role are still quite debatable. Future research will further elucidate the precise role of these chemokines in atherosclerosis and determine the potential of chemokine-based therapies. The Author(s), 2015 Cardiovascular disease nationallicence Atherosclerosis nationallicence Chemokines nationallicence Macrophage migration inhibitory factor nationallicence CXCL12 nationallicence van der Vorst Emiel Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut Döring Yvonne Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut Weber Christian Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut Journal of Molecular Medicine Springer Berlin Heidelberg 93/9(2015-09-01), 963-971 0946-2716 93:9<963 2015 93 109 https://doi.org/10.1007/s00109-015-1317-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00109-015-1317-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- van der Vorst Emiel Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut NATIONALLICENCE 700 1- Döring Yvonne Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut NATIONALLICENCE 700 1- Weber Christian Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr 9, 80336, Munich, Germany aut NATIONALLICENCE 773 0- Journal of Molecular Medicine Springer Berlin Heidelberg 93/9(2015-09-01), 963-971 0946-2716 93:9<963 2015 93 109